Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff.

With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth ...

Stock availability and pricing subject to change depending on retailer or outlet. You can toggle all your mods on/off with a single button press in patch 8 If you’re the kind of person who enjoys ...

If there’s one thing (other than Adriene’s soothing voice) that’ll motivate me to roll out my mat in the morning, it’s a good pair of yoga pants that look cute and actually stay put when I ...

Two children have undergone urgent surgeries in the first few months of this year in South Australia after swallowing a button battery. The parents of a 15-month-old toddler say they feel lucky ...

Novo Nordisk launched a direct-to-consumer program last week to sell Wegovy at a reduced price for people who are uninsured or insured on commercial plans that don't cover the obesity drug. Through ...

Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy ...

Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the hyper-competitive market for obesity drugs. Morten Lammert will join Roche as its ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest ...

Novo announced results from a new weight loss drug that failed to meet expectations. Despite the results, the company is still in a strong position to continue leading the weight loss space. Novo ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...